Monopar Therapeutics Inc. (MNPR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Monopar Therapeutics Inc. (MNPR) Healthcare & Pipeline Overview

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics, with a primary focus on Validive, a treatment for oral mucositis, and Camsirubicin, a treatment for advanced soft tissue sarcoma. The company also develops MNPR-101 and MNPR-202 for various cancers.

What Is the Investment Thesis for MNPR?

Monopar Therapeutics Inc. presents a high-risk, high-reward investment opportunity typical of clinical-stage biopharmaceutical companies. The primary value driver is the successful completion of Phase 2b/3 clinical trials for Validive, targeting a significant unmet need in preventing oral mucositis. Positive trial results and subsequent FDA approval could lead to substantial revenue generation. Camsirubicin's progress in Phase 1b trials for advanced soft tissue sarcoma represents a secondary value driver. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding to support ongoing research and development. The company's market capitalization of $737M reflects the speculative nature of its pipeline.

Based on FMP financials and quantitative analysis

MNPR Key Highlights

Lead product candidate Validive is in Phase 2b/3 clinical trials for the prevention of chemoradiotherapy induced severe oral mucositis.

• Camsirubicin, an analog of doxorubicin, is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma.
• Collaborations with Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore.
• Market capitalization of $737M reflects the company's clinical-stage status.
• The company has 14 employees, indicating a lean operational structure.

Who Are MNPR's Competitors?

MNPR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MNPR's Key Strengths?

Lead product candidate in Phase 2b/3 clinical trials.

• Diverse pipeline of cancer therapeutics.
• Collaborations with reputable research institutions.
• Experienced management team.

What Are MNPR's Weaknesses?

Clinical-stage company with no approved products.

• Reliance on successful clinical trial outcomes.
• Need for additional funding to support research and development.
• Small number of employees.

What Could Drive MNPR Stock Higher?

Completion of Phase 2b/3 clinical trials for Validive.

• Announcement of Phase 1b clinical trial results for Camsirubicin.
• Progression of MNPR-101 and MNPR-202 through preclinical and clinical studies.
• Expansion of strategic collaborations with research institutions and pharmaceutical companies.

What Are the Key Risks for MNPR?

Negative return on equity (-12.8%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $2.0M recently.
• Clinical trial failures for Validive, Camsirubicin, or other product candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies with greater resources.
• Need for additional funding to support research and development.
• Patent challenges or loss of intellectual property protection.

What Are the Growth Opportunities for MNPR?

• Successful Completion of Validive Clinical Trials: The successful completion of Phase 2b/3 clinical trials for Validive represents a significant growth opportunity for Monopar. Oral mucositis is a common and debilitating side effect of cancer treatment, and Validive could address a substantial unmet need. Positive trial results could lead to FDA approval and commercialization, potentially generating significant revenue.
• Advancement of Camsirubicin: The advancement of Camsirubicin through clinical trials for the treatment of advanced soft tissue sarcoma offers another growth avenue. Soft tissue sarcoma is a rare and aggressive cancer, and new treatment options are needed. Positive results from Phase 1b trials could lead to further clinical development and potential commercialization. The market for soft tissue sarcoma treatments is a niche market with potential for high pricing.
• Development of MNPR-101 and MNPR-202: The development of MNPR-101, a urokinase plasminogen activator receptor targeted antibody, and MNPR-202, an analog of camsirubicin, presents additional growth opportunities. These compounds target various types of cancer and could potentially expand Monopar's product pipeline. Preclinical and clinical studies will be necessary to assess their safety and efficacy.
• Strategic Collaborations: Monopar's collaborations with the Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore provide access to expertise, resources, and potential funding. These collaborations can accelerate the development of Monopar's product pipeline and expand its market reach. Strategic partnerships are crucial for small biotechnology companies to navigate the complex drug development process.
• Expansion into New Therapeutic Areas: While currently focused on cancer therapeutics, Monopar could potentially expand into new therapeutic areas in the future. The company's expertise in drug development and its existing pipeline could be leveraged to address other unmet medical needs. This diversification could reduce the company's reliance on its current product candidates and create new growth opportunities. However, this would require significant investment and strategic planning.

What Are MNPR's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Clinical trial data demonstrating efficacy and safety.
• Collaborations with leading research institutions.
• Expertise in cancer drug development.

What Does MNPR Do?

Monopar Therapeutics Inc., incorporated in 2014 and headquartered in Wilmette, Illinois, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for cancer treatment. The company's lead product candidate, Validive, is a clonidine hydrochloride mucobuccal tablet currently in Phase 2b/3 clinical trials. Validive is designed to prevent severe oral mucositis induced by chemoradiotherapy in patients with oropharyngeal cancer. In addition to Validive, Monopar is developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trials for treating advanced soft tissue sarcoma. The company's pipeline also includes MNPR-101, a urokinase plasminogen activator receptor targeted antibody for various cancers; MNPR-101 RIT, a radioimmunotherapeutic for cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin for doxorubicin- and camsirubicin-resistant cancers. Monopar collaborates with the Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore to advance its research and development efforts.

What Products and Services Does MNPR Offer?

• Develop therapeutics for the treatment of cancer.
• Focus on Validive, a treatment for oral mucositis.
• Develop Camsirubicin, a treatment for advanced soft tissue sarcoma.
• Develop MNPR-101, a urokinase plasminogen activator receptor targeted antibody for various cancers.
• Develop MNPR-101 RIT, a radioimmunotherapeutic for cancer and severe COVID-19.
• Develop MNPR-202, an analog of camsirubicin for doxorubicin- and camsirubicin-resistant cancers.
• Collaborate with research institutions and companies to advance drug development.

How Does MNPR Make Money?

• Develop and commercialize cancer therapeutics.
• Generate revenue through product sales upon regulatory approval.
• Collaborate with other companies and research institutions to share costs and expertise.
• Seek funding through venture capital, grants, and partnerships.

What Industry Does MNPR Operate In?

Monopar Therapeutics Inc. operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. The company focuses on developing cancer therapeutics, a market driven by increasing cancer prevalence and the demand for innovative treatments. Monopar's success depends on its ability to navigate the regulatory landscape, secure funding, and differentiate its products from existing therapies. The biotechnology industry is experiencing growth, driven by technological advancements and increased investment in cancer research.

Who Are MNPR's Key Customers?

• Patients with cancer.
• Hospitals and oncology clinics.
• Healthcare providers.
• Research institutions.

Over the past six months, Monopar Therapeutics Inc. insiders filed 45 SEC Form 4 transactions — 29 sales and 16 purchases. On net that is roughly 6K shares disposed (about $2.0M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Monopar Therapeutics Inc.

Revenue for Monopar Therapeutics Inc. came in at $0 during Q2 FY2026. The company recorded a net loss of $5.3M, with diluted EPS of $-0.62. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, MNPR averaged $-0.58 in diluted EPS.

MNPR Valuation & Market Position

With a $737M market cap, Monopar Therapeutics Inc. sits in the small-cap segment of the market. Analyst price targets span from $105.00 to $133.00, with a consensus of $123.57. At the current price of $109.96, that implies approximately 12% upside potential. Relative to its peer group, MNPR's quantitative score of 57/100 is below the peer average of 85/100.

Return on equity for Monopar Therapeutics Inc. stands at -12.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 56.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.8%, the inverse of the P/E and a quick read on earnings relative to price.

Monopar Therapeutics Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Monopar Therapeutics Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 49.5% below estimates on average.

Company Profile

Monopar Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wilmette, US. The company is led by CEO Chandler D. Robinson. MNPR has traded publicly since 2019.

MNPR Financials

MNPR Latest News

MNPR Analyst Consensus

MNPR MoonshotScore

Monopar Therapeutics Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources